Clinical evaluation of anti-tumor effect of carboplatin on oral squamous cell carcinoma. Multi-center study.:—multi-center study—

スポンサーリンク

概要

• 論文の詳細を見る

• Multi-center study to evaluate the anti-tumor effect and toxicity of carboplatin (CBDCA) on oral squamous cell carcinoma was conducted. Thirty-four patients, 28 males and 6 females aged 38 to 78 years (mean age 63 years) who agreed to participate in this trial were selected from 7 hospitals. CBDCA (300-400mg/m<SUP>2</SUP>) combined with UFT (400mg/m<SUP>2</SUP>/day, p.o.) or 5-FU (250-500mg/body/day, i.v. or i.a.) was administered intravenously to these patients.<BR>The clinical response was evaluated 4 weeks after beginning this study. Seven patients were excluded from evaluation of the anti-tumor effect caused by irregular course of admini-stration of medicines and another one was unmeasurable 4 weeks later. Therefore, the response could be evaluated in 26 patients UFT was administrated to 22 of 26 patients for 4 weeks and 5-FU to 4 patients for 4 or 5 days immediately after prescription of CBDCA. Eighteen of the 26 patients were previously untreated and 8 had been recurrent cases. In a distribution of stage in these 18 previously untreated patients, 3 were stage II, 6 stage III and 9 stage IV cases. For evaluation of CBDCA toxicity, all 34 cases were used. A complete response was obtained in two cases and partial response in 9 cases, the overall response rate was 42.3%. Among the 18 previously untreated patients, a complete response was obtained in 2 cases and partial response in 7 cases (response rate 50.0%) . Among the 8 recurrent cases, a partial response was observed in only 2 cases (response rate 25.0%) . In stage IV cases, the highest response rate (66.7%) was obtained. In stages II and III, 33.3% of the patients showed a partial response respectively. Relatively severe myelosuppression was observed. Thrombocytopenia occurred in 55.8% of 43 courses (34 patients), leukocytopenia occurred in 58.1% and a decrease of hemoglobin was observed in 74.4%. Grade IV thromboocytopenia occurred in two courses and grade IV leukocytepenia in one course. Nausea occurred in 10 of the 34 patients and vomiting in 4 patients. Granisetron was useful to prevent to nausea and vomiting caused by CBDCA.

• 一般社団法人 日本口腔腫瘍学会の論文

一般社団法人 日本口腔腫瘍学会 | 論文

• 進行口腔癌に対する逆行性超選択的動注化学療法, 放射線同時併用療法後の救済手術
• TS-1による化学療法と温熱放射線療法が著効した後発頸部リンパ節転移の1例
• 手術シミュレーションに基づく腫瘍分割摘出により顎骨を保存した得た下顎骨骨形成線維腫の1例
• 口腔癌における化学・放射線療法後の再発・二次再建に関する外科療法の検討
• 下顎骨再建 : 血管柄付遊離骨移植と遊離軟部組織移植の比較

もっと見る

スポンサーリンク